Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Mapping the journey to an HIV vaccine.

Ackerman M, Alter G.

N Engl J Med. 2013 Jul 25;369(4):389-91. doi: 10.1056/NEJMcibr1304437. No abstract available.

PMID:
23883384
2.

AIDS/HIV. A boost for HIV vaccine design.

Burton DR, Weiss RA.

Science. 2010 Aug 13;329(5993):770-3. doi: 10.1126/science.1194693. No abstract available.

PMID:
20705840
3.

PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.

Fauci AS, Marston HD.

Science. 2015 Jul 24;349(6246):386-7. doi: 10.1126/science.aac6300. Epub 2015 Jul 23. No abstract available.

PMID:
26206922
4.

HIV vaccine development--improving on natural immunity.

Johnston MI, Fauci AS.

N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621. No abstract available.

5.

A pathway to HIV-1 neutralization breadth.

Smith SA, Derdeyn CA.

Nat Med. 2015 Nov;21(11):1246-7. doi: 10.1038/nm.3989. No abstract available.

6.

Challenges for structure-based HIV vaccine design.

Schief WR, Ban YE, Stamatatos L.

Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Review.

PMID:
20048708
7.

HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.

Wren L, Kent SJ.

Hum Vaccin. 2011 Apr;7(4):466-73. Epub 2011 Apr 1. Review.

PMID:
21389779
8.

Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.

Parsons MS, Rouleau D, Routy JP, LeBlanc R, Grant MD, Bernard NF.

AIDS. 2011 Jun 19;25(10):1249-64. doi: 10.1097/QAD.0b013e328347f9fa.

PMID:
21516028
9.
10.

HIV vaccine design: the neutralizing antibody conundrum.

Stamatatos L.

Curr Opin Immunol. 2012 Jun;24(3):316-23. doi: 10.1016/j.coi.2012.04.006. Epub 2012 May 15. Review. No abstract available.

PMID:
22595693
11.

HIV: Roadmaps to a vaccine.

Mouquet H, Nussenzweig MC.

Nature. 2013 Apr 25;496(7446):441-2. doi: 10.1038/nature12091. Epub 2013 Apr 3. No abstract available.

PMID:
23552894
12.

"Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies.

Dimitrov JD, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S.

PLoS Pathog. 2011 Jun;7(6):e1002095. doi: 10.1371/journal.ppat.1002095. Epub 2011 Jun 16. Review. No abstract available.

13.

Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1.

Kwong PD, Mascola JR, Nabel GJ.

Cell Host Microbe. 2009 Oct 22;6(4):292-4. doi: 10.1016/j.chom.2009.09.008.

14.

Broadly Neutralizing Antibodies and the Development of Vaccines.

Haynes BF, Bradley T.

JAMA. 2015 Jun 23-30;313(24):2419-20. doi: 10.1001/jama.2015.2427. No abstract available.

PMID:
26103022
15.

Broadly neutralizing antibodies and their significance for HIV-1 vaccines.

González N, Alvarez A, Alcamí J.

Curr HIV Res. 2010 Dec;8(8):602-12. Review.

PMID:
21054253
16.

HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Doria-Rose NA.

J Infect Dis. 2010 Apr 1;201(7):981-3. doi: 10.1086/651143. No abstract available.

17.

Vaccines to antibodies: grow up!

von Bubnoff A.

IAVI Rep. 2010 Jul-Aug;14(4):4-9.

18.

Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.

Charles-Niño C, Pedroza-Roldan C, Viveros M, Gevorkian G, Manoutcharian K.

Vaccine. 2011 Jul 18;29(32):5313-21. doi: 10.1016/j.vaccine.2011.05.007. Epub 2011 May 19.

PMID:
21600948
19.

Infectious disease. An enterprising time for HIV vaccine research.

Cohen J.

Science. 2012 Sep 21;337(6101):1446. No abstract available. Erratum in: Science. 2012 Nov 9;338(6108):742.

PMID:
22997300
20.

Novel adjuvants for B cell immune responses.

Loré K, Karlsson Hedestam GB.

Curr Opin HIV AIDS. 2009 Sep;4(5):441-6. doi: 10.1097/COH.0b013e32832da082. Review.

PMID:
20048709

Supplemental Content

Support Center